Davis Capital Management
VRTX icon

Davis Capital Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Davis Capital Management’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$4.18K Hold
8
– – ﹤0.01% 326
2026
Q2 		$3.97K Buy
8
+5
+167% +$2.22K ﹤0.01% 333
2026
Q1 		$1.34K Buy
3
+1
+50% +$466 ﹤0.01% 315
2025
Q4 		$907 Hold
2
– – ﹤0.01% 342
2025
Q3 		$783 Buy
+2
New +$836 ﹤0.01% 358

Other funds holding VRTX

Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return
Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $83.2B AUM 35.34% 1-Year Est. Return
AMF Tjänstepension
AMF Tjänstepension Stockholm, Sweden $17.2B AUM 28.3% 1-Year Est. Return
Davenport & Co
Davenport & Co Richmond, Virginia $19.9B AUM 12.67% 1-Year Est. Return
New York State Teachers Retirement System (NYSTRS)
New York State Teachers Retirement System (NYSTRS) Albany, New York $52.9B AUM 36.03% 1-Year Est. Return
Montrusco Bolton Investments
Montrusco Bolton Investments Montreal, Quebec, Canada $5.77B AUM 24.61% 1-Year Est. Return
Birch Hill Investment Advisors
Birch Hill Investment Advisors Boston, Massachusetts $2.43B AUM 15.45% 1-Year Est. Return
Fjarde Ap-fonden
Fjarde Ap-fonden Stockholm, Sweden $19.4B AUM 31.69% 1-Year Est. Return
KBC Group
KBC Group Brussels, Belgium $47.9B AUM 37.61% 1-Year Est. Return
Provident Investment Management
Provident Investment Management Novi, Michigan $999M AUM 19.45% 1-Year Est. Return

Davis Capital Management's VRTX Position: Q3 2026 in Review

Davis Capital Management held its Vertex Pharmaceuticals (VRTX) position steady in Q3 2026 at 8 shares worth $4.18K. The position accounts for ﹤0.01% of the portfolio, ranked #326.

Davis Capital Management first reported a position in VRTX in Q3 2025 and has held it in 5 quarters since. 521 funds tracked by Wall St. Rank hold VRTX as of Q3 2026.

  • Davis Capital Management held 8 shares of Vertex Pharmaceuticals worth $4.18K as of Q3 2026.
  • Davis Capital Management left its Vertex Pharmaceuticals share count unchanged in Q3 2026.
  • Vertex Pharmaceuticals made up ﹤0.01% of Davis Capital Management's portfolio in Q3 2026, its #326 holding.
  • Davis Capital Management first reported a position in Vertex Pharmaceuticals in Q3 2025 and has held it in 5 quarters since.
  • 521 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2026.

Based on Davis Capital Management's 13F filing for Q3 2026, filed 8 Oct 2026.